How Can Fatty Liver Lead to Liver Cancer and How Can We Simply Assess It?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA20022U3" target="_blank" >RIV/61988987:17110/19:A20022U3 - isvavai.cz</a>

Výsledek na webu

<a href="https://actascientific.com/ASGIS/pdf/ASGIS-02-0100.pdf" target="_blank" >https://actascientific.com/ASGIS/pdf/ASGIS-02-0100.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.31080/ASGIS.2019.02.0100" target="_blank" >10.31080/ASGIS.2019.02.0100</a>

Jazyk výsledku

angličtina

Název v původním jazyce

How Can Fatty Liver Lead to Liver Cancer and How Can We Simply Assess It?

Popis výsledku v původním jazyce

Background: In 2016, more than 1.9 billion adult populations were overweight, 650 million of them were obese, which represents around 13% of the world's adult population. Liver steatosis has become the most common chronic liver disease in developed countries. In most cases, non-alcoholic fatty liver disease (NAFLD) is a benign and reversible liver disorder. Under certain circumstances, the disease may result through the image of non-alcoholic steatohepatitis (NASH) and hepatic fibrosis to liver cirrhosis with all known negative consequences, until formation of hepatocellular carcinoma (HCC). Methods: We searched from the Pubmed, Google Scholar and Research gate database and looked for keywords NAFLD, steatohepatitis, steatohepatitic variant of HCC. Results: The pathogenesis of NAFLD and metabolic syndrome seems to have common pathophysiological mechanisms. Although liver biopsy remains the gold standard for NAFLD diagnosis, it seems that new diagnostic procedures and scoring systems are emerging that could non-invasively distinguish simple steatosis from NASH. Conclusion: A higher number of metabolic syndrome risk factors have been registered in patients with steatohepatitic HCC variant. HCC patients with clinical symptoms have a very poor prognosis (median 5-year overall survival is between 0-10%); on the other hand, patients with asymptomatic HCC detected by screening show a higher survival rate, with a total 5-year survival of more than 50 % due to radical treatment. Simple and unassuming diagnostic methods can be used in a wide range of patients, thus systematically preventing the development of diseases and related disorders. Early diagnosis and risk stratification are essential for effective treatment management.

Název v anglickém jazyce

How Can Fatty Liver Lead to Liver Cancer and How Can We Simply Assess It?

Popis výsledku anglicky

Background: In 2016, more than 1.9 billion adult populations were overweight, 650 million of them were obese, which represents around 13% of the world's adult population. Liver steatosis has become the most common chronic liver disease in developed countries. In most cases, non-alcoholic fatty liver disease (NAFLD) is a benign and reversible liver disorder. Under certain circumstances, the disease may result through the image of non-alcoholic steatohepatitis (NASH) and hepatic fibrosis to liver cirrhosis with all known negative consequences, until formation of hepatocellular carcinoma (HCC). Methods: We searched from the Pubmed, Google Scholar and Research gate database and looked for keywords NAFLD, steatohepatitis, steatohepatitic variant of HCC. Results: The pathogenesis of NAFLD and metabolic syndrome seems to have common pathophysiological mechanisms. Although liver biopsy remains the gold standard for NAFLD diagnosis, it seems that new diagnostic procedures and scoring systems are emerging that could non-invasively distinguish simple steatosis from NASH. Conclusion: A higher number of metabolic syndrome risk factors have been registered in patients with steatohepatitic HCC variant. HCC patients with clinical symptoms have a very poor prognosis (median 5-year overall survival is between 0-10%); on the other hand, patients with asymptomatic HCC detected by screening show a higher survival rate, with a total 5-year survival of more than 50 % due to radical treatment. Simple and unassuming diagnostic methods can be used in a wide range of patients, thus systematically preventing the development of diseases and related disorders. Early diagnosis and risk stratification are essential for effective treatment management.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30212 - Surgery

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Scientific Gastrointestinal Disorders

ISSN

2582-1091

e-ISSN

—

Svazek periodika

2

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

IN - Indická republika

Počet stran výsledku

7

Strana od-do

37-43

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—